Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50626
Name gastrointestinal neuroendocrine tumor
Definition A gastrointestinal system cancer that has_material_basis_in neuroendocrine cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer gastrointestinal neuroendocrine tumor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02250885 Phase II Selinexor KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed USA 0
NCT02315625 Phase II Everolimus Sunitinib Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery Terminated USA 0
NCT02687958 Phase II Everolimus Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin Unknown status ITA 0
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting USA 1
NCT02936323 Phase Ib/II PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed USA 1
NCT02955069 Phase II Spartalizumab Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 4
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Completed USA 0
NCT03043664 Phase Ib/II Lanreotide acetate + Pembrolizumab Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET) Active, not recruiting USA 0
NCT03049189 Phase III 177Lu-edotreotide Everolimus Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 7
NCT03095274 Phase II Durvalumab Tremelimumab Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) Active, not recruiting ESP 0
NCT03278379 Phase II Avelumab Avelumab in G2-3 NET (NET-002) Unknown status CAN 0
NCT03278405 Phase Ib/II Avelumab Avelumab in G3 NEC (NET-001) Completed CAN 0
NCT03411915 Phase I XmAb18087 A Study of XmAb18087 in Subjects With NET and GIST Completed USA 0
NCT03420521 Phase II Ipilimumab + Nivolumab Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors Active, not recruiting USA 0
NCT03670030 Phase II Nab-rapamycin A Study to Test the Effectiveness of ABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System Terminated USA 0
NCT03879694 Phase I Octreotide + Sargramostim + SurVaxM Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors Recruiting USA 0
NCT03891784 Phase II Abemaciclib Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Recruiting USA 0
NCT03901378 Phase II Carboplatin + Etoposide + Pembrolizumab Pembrolizumab Cisplatin + Etoposide + Pembrolizumab Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma Withdrawn USA 0
NCT03972488 Phase III Octreotide acetate lutetium Lu 177 dotatate + Octreotide acetate Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2) Recruiting USA | ITA | FRA | ESP | DEU | CAN 5
NCT03980925 Phase II Carboplatin + Etoposide + Nivolumab Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Recruiting ESP 0
NCT04086485 Phase Ib/II lutetium Lu 177 dotatate + Olaparib Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) Not yet recruiting USA 0
NCT04123262 Phase II Tamoxifen Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression Recruiting USA 0
NCT04400474 Phase II Atezolizumab + Cabozantinib Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study (CABATEN) Recruiting ESP 0
NCT04427787 Phase II Cabozantinib + Lanreotide acetate A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA) Recruiting ITA 0
NCT04525638 Phase II lutetium Lu 177 dotatate + Nivolumab A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours Recruiting ESP 0
NCT04609592 Phase I lutetium Lu 177 dotatate Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery Recruiting USA 0
NCT04893785 Phase II Cabozantinib + Temozolomide A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) (CABOTEM) Recruiting ITA 0
NCT04919226 Phase III Fluorouracil + Leucovorin + Oxaliplatin 177Lu-edotreotide Everolimus Capecitabine + Temozolomide Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE) Recruiting USA | FRA | ESP 4
NCT05249114 Phase I Cabozantinib + lutetium Lu 177 dotatate Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors Not yet recruiting USA 0
NCT05262556 Phase I Ipilimumab + Nivolumab + Thymoquinone TQ (Thymoquione) Formula With Nivolumab and Ipilimumab in Gastroenteropancreatic Neuroendocrine Carcinomas Not yet recruiting USA 0
NCT05364944 Phase I Debio 4126 + Lanreotide acetate Debio 4126 + Octreotide acetate A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01) Recruiting ITA | FRA | ESP | DEU 8